Same Drug Class

Osimertinib vs Pembrolizumab

Osimertinib vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between Osimertinib and Pembrolizumab.

Mechanism of Action

Osimertinib: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Osimertinib — 48 hours; Pembrolizumab — 26 days.

Chemical Properties

Molecular Formula: Osimertinib — C28H33N7O2.

Molecular Weight: Osimertinib — 499.6050 g/mol.

Type: Osimertinib — Small molecule; Pembrolizumab — Antibody.